2021 Fiscal Year Final Research Report
Basic research on multi-step tongue carcinogenesis model for realizing clinical sequence
| Project/Area Number |
19K10069
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 57020:Oral pathobiological science-related
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山崎 学 新潟大学, 医歯学系, 講師 (10547516)
丸山 智 新潟大学, 医歯学総合病院, 講師 (30397161)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 口腔細胞診 / 液状化検体細胞診(LBC) / 口腔がん / モデル動物 / Carcinoma Sequence / クリニカルシークエンス |
|---|
| Outline of Final Research Achievements |
OSCC arises from oral epithelial dysplasia; however, there is no useful marker for early OSCC detection, likely owing to the inability to continuously observe the carcinoma sequence. We aimed to establish an experimental model to observe changes in the sequential expression patterns of mRNAs and proteins in the same rat using liquid-based cytology techniques. Cytology specimens were collected from a 4NQO-induced rat tongue cancer model at every 3 weeks. We examined candidate biomarker expression using immunocytochemistry and qRT-PCR. The labeling index (LI) was calculated as the percentage of positively stained nuclei. Brd4 and c-Myc mRNA levels were upregulated during progression from NILM to OSCC. BRD4- and c-Myc-LI were increased in LSIL, HSIL, and OSCC.
BRD4 and c-Myc are effective in classifying lesions of NILM and LSIL or higher, and could be useful diagnostic markers for the early detection of oral cancer.
|
| Free Research Field |
口腔病理学分野
|
| Academic Significance and Societal Importance of the Research Achievements |
本邦の口腔がんは,過去10年間で２倍以上増加し,年間８千名の死亡者と報告されているが,厚生労働省がんでは“希少がん”に分類されているために広く国民に知られてなく,また有力なマーカーや治療薬がない上に口腔がん検診の予防対策も不十分なままである.
そこで口腔がん発生モデル動物をLBC法に応用すれば,発がん段階で屠殺せず継時的かつ同一検体内で観察が可能である.また標本や免疫染色及び次世代シークエンスやメタボロミクス解析が可能となることから早期判定用マーカーを見出すだけで無く,革新的な診断や分子標的療法が確立でき,クリニカルシークエンスに繋がる個別医療などに対してもブレイクスルーが期待できる.
|
